The usefulness of %[ − 2] proPSA and Prostate Health Index (phi) in the detection of prostate cancer are currently unknown. It has been suggested that these tests can distinguish prostate cancer from benign prostatic diseases better than PSA or %fPSA. We performed a systematic review and meta-analysis of the available scientific evidence to evaluate the clinical usefulness of %[ − 2] proPSA and phi. Relevant published papers were identified by searching computerized bibliographic systems. Data on sensitivity and specificity were extracted from 12 studies: 10 studies about %[ − 2] proPSA (3928 patients in total, including 1762 with confirmed prostate cancer) and eight studies about phi (2919 patients in total, including 1515 with confirmed prostate cancer). The sensitivity for the detection of prostate cancer was 90% for %[ − 2] proPSA and phi, while the pooled specificity was 32.5% (95% CI 30.6 -34.5) and 31.6% (95% CI 29.2 -34.0) for %[ − 2] proPSA and phi, respectively. The measurement of %[ − 2] proPSA improves the accuracy of prostate cancer detection in comparison with PSA or %fPSA, particularly in the group of patients with PSA between 2 μ g/L and 10 μ g/L. Similar results were obtained measuring phi. Using these tests, it is possible to reduce the number of unnecessary biopsies, maintaining a high cancer detection rate. Published results also showed that %[ − 2] proPSA and phi are related to the aggressiveness of the tumor.
Introduction
Prostate specific antigen (PSA) is a serum tumor marker that is widely used in the early detection of prostate cancer. However, since the specificity (Sp) of PSA is limited, biopsy is positive in approximately 25% of patients with PSA in the range between 2 μ g/L and 10 μ g/L [ 1 ] . Furthermore, prostate cancer is detected on repeated biopsy in 10% -35% of patients with a negative first biopsy. So, according to the guidelines of the European Association of Urology, it is necessary to repeat the biopsy in these patients [ 2 ] .
The measurement of the several fractions of PSA (free PSA, complexed PSA) has been proposed with the aim to improve the Sp of total PSA. A meta-analysis, published in 2005, showed that the use of the percentage of free PSA (%fPSA) is useful to improve the detection of prostate cancer [ 3 ] . More recently, fPSA has been found to include the subforms BPSA, iPSA and proPSA [ 4 , 5 ] . BPSA and iPSA are associated with benign tissue, but proPSA is associated with cancer. It is possible to detect three truncated forms of proPSA in serum, [ − 2] , [ − 4 ] and [ − 5, − 7] , with [ − 2] proPSA being the most stable form. Several studies suggested the clinical usefulness of proPSA in the detection of prostate cancer using different non-commercial assays, including the measurement of the cumulative sum of all truncated forms [ 6 , 7 ] and the measurement of [ − 5, − 7] proPSA [ 8 , 9 ] . However, these tests have not been shown to be as useful as the new assay for the measurement of [ − 2] proPSA. Also, the use of a panel of four kallikrein markers -total PSA, free PSA, intact PSA and hK2 -in the detection of prostate cancer has been proposed by recent studies [ 10 , 11 ] .
The development of the [ − 2] proPSA assay by Beckman Coulter opens a new field of study in the detection of prostate cancer. Currently, several studies have suggested that in men with a total PSA between 2.5 μ g/L and 10 μ g/L, the percentage of [ − 2] proPSA to fPSA (%[ − 2] proPSA) can distinguish between malignant and benign prostate diseases better than total PSA or %fPSA. Also, several studies underlined the usefulness of the Prostate Health Index (phi), a mathematical combination of total PSA, fPSA and [ − 2] proPSA according to the formula [ − 2] proPSA/fPSA) × √ tPSA.
The objective of this systematic review was to assess the usefulness of %[ − 2] proPSA and phi in the detection of prostate cancer. A critical analysis of results referring to the relationship between these tests and the aggressiveness of prostate cancer was also performed.
Methods
Meta-analysis was performed in accordance with the preferred reporting items from systematic reviews and meta-analysis (consensus PRISMA) adapted to studies of diagnostic tests [ 12 ] . In short, the PRISMA statement is a consensus that intends to inform by evidence whenever possible and consists of a 27-item checklist and a four-phase flow diagram that are available for researchers on internet for free (http://www.prisma-statement. org/).
Search strategy and study selection
A systematic search of several electronic databases was performed: MedLine, Embase, Cancerlit, Cochrane Library, Web of Science and Scopus. A strategy search in title, abstract or keyword lists was done looking for combinations of the following search terms: as medical subject headings MeSH ( " Prostatic Neoplasms " , " Sensitivity and Specificity " , " Diagnosis " , " Evidence-Based Medicine " ) and as free search terms ( " proPSA " , " p2PSA " , " [ − 2]proPSA " , " [ − 2]proenzyme prostate specific antigen " , " Prostate Health Index " , " phi " , " Prostate tumor " , " Prostate tumour " ). This literature search was complemented with the review of three specialized journals in Urology (European Urology, Journal of Urology and Prostate) from January 1990 to December 2011. Furthermore, the authors checked the cited bibliographies of selected studies and contacted experts.
To avoid duplication of information, when the same population was reported in several publications, priority was given to scientific articles over meeting abstracts or in case there was more than a scientific article, the most complete study was chosen.
Eligibility criteria
All the studies about diagnostic tests and systematic review about %[ − 2] proPSA and phi were considered eligible for inclusion if they met the following criteria: original data and confirmation of prostate cancer on biopsy. There were no language restrictions.
Data extraction
All the studies were assessed independently by both researchers to determine study inclusion. Both reviewers, separately, screened all titles and excluded studies if obviously irrelevant and removed duplicate citations. When there was any doubt concerning the eligibility of a study, the abstract was examined and, if necessary, the full text. After selecting relevant studies, data extraction was carried out using a standardized form. The analysis of the concordance between both researchers about the eligibility of a study and the values of true positive (TP), false-posi tive (FP), false negative (FN) and true negative (TN) was done by calculating the kappa index. Disagreements about eligibi lity and data extraction were resolved by consensus.
Assessment of risk of bias
The quality of the selected studies was assessed by using quality assessment of diagnostic accuracy studies (QUADAS) [ 13 ] . The QUADAS tool consists of a set of 14 items, phrased as questions, each of which should be scored as yes, no or unclear. Possible sources of heterogeneity between studies were examined. Methodological heterogeneity or differences in design or quality were asses sed during the selection of relevant studies and statisti cal hete rogeneity was measured using I 2 scores and the χ 2 -test. The protocol was prepared a priori and this study was done in accordance with the Research Ethics Committee of M ú tua Terrassa Hospital, Barcelona, Spain.
Data analysis
For each study, 2 × 2 tables for each test with TP, FP, FN and TN results using data extraction from the original referred scientific articles were performed. Pooled estimates of sensitivity (Se) and Sp as the main outcome measures were calculated as well as the limits of the 95% confidence intervals for such values. Forest plot was represented as figures. Methodological heterogeneity was assessed during selection.
The threshold effect is a characteristic source of hetero geneity in the meta-analysis of diagnostic tests and arises when the included studies uses different cut-off points to define what is considered as a positive result of a diagnostic test. The analysis of diagnostic threshold was assessed through receiver operating characteristic (ROC) plane and correlation coefficient Spearman. The ROC plane is the graphic representation of the pairs of Se and Sp and, characteristically its points show a curvilinear pattern if the threshold effect exists. Statistical heterogeneity was measured using the χ 2 -test and I 2 scores. I 2 score was used as a measure of the inconsistency between studies in the meta-analysis and was interpreted as low (25% -50%), moderate (51% -75%) and high ( > 75%). Data were analyzed using a free statistical software package Metadisc version 1.4 [ 14 ] , with the only exception of the analysis of the concordance between reviewers and kappa index which was performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA).
Assays used in the references evaluated in this study
In the studies corresponding to references [ 15 -27 ] the concentrations of [ − 2] proPSA were measured in a Beckman Coulter ACCESS ® immunoassay system, using dual monoclonal antibodies. [ − 2] proPSA was measured in references [ 28 , 29 ] using a dual monoclonal sandwich assay in a microtiter plate. PSA and fPSA were measured using a Beckman Coulter ACCESS ® immunoassay system in references [ 15 -24 ] or Hybritech Tandem PSA and Tandem free PSA assays in reference [ 28 ] . The measurement of PSA and fPSA in reference [ 29 ] was determined with Hybritech Tandem PSA and Tandem free PSA assays (Beckman Coulter, Inc.) in site 2 (Washington University) and with the Abbott total and free PSA assays (Abbott Laboratories, Chicago, IL, USA) in site 1 (Innsbruck University).
Phi was calculated in studies corresponding to references [ 16 -21 , 25 , 27 ] using the formula [ − 2] proPSA/ fPSA) × √ tPSA.
Results
Two hundred and thirteen potentially relevant references were obtained by electronic databases and supplementary sources in our systematic search. The results of the search and study selection process are shown in Figure 1 . There were 31 articles requiring full-text review, and 12 studies were finally included in the meta-analysis. Data on Se and Sp were pooled from 10 studies for % cancer) and eight studies about phi (2919 patients in total, including 1515 with confirmed prostate cancer).
The study by Jansen et al. [ 15 ] contained two different populations (Rotterdam and Innsbruck), and was treated as two separate studies.
The results about concordance between both reviewers had a coincidence of 94% and a kappa index of 0.812 (95% CI 0.635 -0.990).
The quality assessment of the eligible studies was moderate-high according to QUADAS scale ( Table 1 ) [ 15 -24 , 28 , 29 ] . The main characteristics about the selected studies are shown in Table 2 including the description of the population of each study, the sampling frame and the criteria and characteristics of prostate biopsy. Table 3 shows the performance of %[ − 2] proPSA and phi and compares the area under the curve (AUC) corresponding to these tests with the AUC for PSA and %fPSA. The accuracy of %[ − 2] proPSA and phi in the detection of prostate cancer is reported in Table 4 . Data presented in this table were extracted from the included studies. Of the 12 studies included, only three specified the cut-off value. The cut-off level for %[ − 2] proPSA at a Se of 90% was 2.5% for Mikolajczyk et al. [ 28 ] and 1.06% for Miyakubo et al. [ 19 ] . The cut-off reported for phi at a Se of 90% was 24.9% for Miyakubo et al. [ 19 ] and 21.1% for Catalona et al. [ 16 ] .
Methodological heterogeneity was assessed before analyses and no studies were excluded due to this reason. The existence of a threshold effect was ruled out after examining the ROC plane and Spearman ' s correlation coefficient (r = 0.636 and p-value = 0.048 for %[ − 2] proPSA and r = 0.262 and p-value = 0.531 for phi).
When revising the studies, it was found that they had in common the results for sensibility of 90% and therefore it was decided to extract the data and perform calculations to this Se. There was a high degree of statistical heterogeneity ( 
Discussion
A low %fPSA has been shown to be associated with prostate cancer and several studies have indicated that this test is useful in reducing the number of negative biopsies [ 3 ] . However, currently, we know that fPSA is composed of three distinct molecular forms, which are associated differently with cancer. Initial clinical studies showed that proPSA may be a useful marker for the detection of prostate cancer, and more recently Beckman Coulter introduced a new immunoassay for the measurement of the [ − 2] proPSA, a stable form of proPSA [ 30 ] .
This meta-analysis is the first study that shows the available information on the clinical usefulness of this tumor marker in the detection of prostate cancer. Data on Se and Sp about %[ − 2] proPSA and the derivative test phi were extracted from 12 eligible studies. At Se of 90%, which is clinically acceptable, the Sp was 32% for %[ − 2] proPSA, ranging between 21% and 49%, and 32% for phi, ranging between 26% and 43%. The AUCs obtained by ROC analysis were also clinically acceptable, with results between 0.635 and 0.780 for %[ − 2] proPSA and between 0.703 and 0.77 for phi.
This study has some limitations. For one, information about the cut-offs used was showed only in three studies [ 16 , 19 , 28 ] ; therefore, there was heterogeneity in primary studies. The high level of inconsistency in the global Sp for %[ − 2] proPSA (89%) and for phi (81%) shows the heterogeneity of the studies included in this meta-analysis. Differences in recruitment strategy, in population characteri stics, and in the number of cores obtained in biopsies may contribute to these variations. We must underline that the same assay was used in the majority of studies, with only two exceptions, corresponding to the earlier references [ 28 , 29 ] that uses a noncommercial assay for the measurement of [ − 2] proPSA. This factor may influence in part in the heterogeneity of results. PSA and fPSA were measured using an equivalent assay (Beckman Coulter ACCESS ® immunoassay or Hybritech Tandem assays) in all studies, only with a partial exception in reference [ 29 ] , that used the Abbott total and free PSA assays in part of the measurements. %[ − 2] proPSA and phi have a similar performance for patients with PSA between 2 μ g/L and 4 μ g/L and for patients with PSA between 4 μ g/L and 10 μ g/L according to different studies [ 17 , 22 , 24 , 29 ] . So, Guazzoni et al. [ 17 ] showed that the AUC for %[ − 2] proPSA is 0.76 for patients with PSA between 2 μ g/L and 4 μ g/L and 0.78 for patients with PSA between 4 μ g/L and 10 μ g/L. For both groups of patients the AUC for phi was 0.76. Similar results were indicated for %[ − 2] proPSA in other studies [ 22 , 24 , 29 ] .
The majority of studies reported in this meta-analysis showed that the AUC for %[ − 2] proPSA (ranging between 0.635 and 0.78) was higher than the AUC for %fPSA. Sokoll et al. [ 22 ] communicated an exception to this criteria, but in this study, too, the AUC for %[ − 2] proPSA was higher to %fPSA in the group of patients with PSA between 2 μ g/L Table 2 Characteristics of the studies included in the review.
ANN, artificial neural network; CaP, prostate cancer; DRE, digital rectal examination; LR, logistic regression; TRUS, transrectal ultrasound. Table 4 Diagnostic accuracy: sensitivity and specificity. Data were extracted from included studies. These results show that the measurement of %[ − 2] proPSA and phi increases the specificity of the detection of prostate cancer hence reducing the number of unnecessary biopsies. However, information about the recommended cut-offs for these tests were not shown in the majority of papers included in our review. The cut-off level for %[ − 2] proPSA at Se of 90% was 2.5% for Mikolajczyk et al. [ 28 ] and 1.06% for Miyakubo et al. [ 19 ] . More similar are the cut-offs suggested for phi by Miyakubo et al. [ 19 ] and Catalona et al. [ 16 ] showing, respectively that 24.9% and 21.1% of phi corresponds to Se of 90%. Published results showed that while the accuracy of PSA declines with age, the %fPSA increases the predictive value of PSA in older patients [ 31 ] . Results communicated by Catalona et al. [ 16 ] indicated that phi does not differ by age, and this test may be applicable to young and older men in the detection of prostate cancer.
However, although the unit cost of [ − 2] proPSA is two to three times higher than both PSA or fPSA, the use of %[ − 2] proPSA and phi for the detection of prostate cancer decreases global costs. The additional blood test costs were compensated by the savings on the costs of physician office visits and the avoidance of unnecessary biopsies [ 32 , 33 ] .
Several authors showed that %[ − 2] proPSA and phi may be related to prostate cancer aggressiveness, with higher levels of these tests in patients with Gleason score higher than 7 and in patients with locally advanced tumors [ 15 , 17 , 22 , 23 ] . This is relevant information because about one-third of new diagnosed tumors have features of insignificant prostate cancer [ 34 ] and these patients can be candidates to active surveillance. However, the identification of these patients using the standard markers, including PSA, biopsy, Gleason score and number of positive biopsy cores, fails to predict accurately the prostate cancer aggressiveness and to choose the more adequate treatment. This point has been confirmed recently by the PIVOT study [ 35 ] comparing the effectiveness of radical prostatectomy versus observation in 731 men with localized prostate cancer. The authors showed absolute reductions in all-cause mortality with radical prostatectomy in patients with PSA higher than 10 μ g/L and possibly for patients with intermediate-or high-risk tumors, but not in patients with low-risk prostate cancer.
These results underline the usefulness of risk factors in the management of patients with prostate cancer in order to select between a radical treatment and active surveillance. Results reported about %[ − 2] proPSA and phi suggest that these tests may distinguish low-and high-risk prostate cancer. Using a multivariate analysis, Guazzoni et al. [ 25 ] showed that the inclusion of %[ − 2] proPSA and phi significantly increased the predictive accuracy of a model based on patient age, PSA, %fPSA, clinical stage and biopsy Gleason score in the prediction of high pathologic stage or high pathologic Gleason score. Similarly, de Vries et al. [ 26 ] indicated promising results for %[ − 2] proPSA in selecting treatment strategies for men with prostate cancer using Epstein ' s criteria to differentiate between non-aggressive and aggressive tumors. Finally, in a recently published study Isharwal et al. [ 27 ] described that %[ − 2] proPSA and phi predicts unfavorable biopsy conversion at an annual surveillance biopsy examination among men enrolled in an active surveillance program. According to this study, the probability of an unfavorable biopsy conversion is higher in patients with %[ − 2] proPSA higher than 0.7 or with phi higher than 34.2.
Conclusions
The available data shows that %[ − 2] proPSA and the derivative test phi may be useful in the detection of prostate cancer reducing the number of negative bio psies and improving results obtained with %fPSA and total PSA. Recent published data, concerning cost-effectiveness of these tests also suggests a positive budget impact of their generalized implementation in the management of prostate cancer. Results about the relationship of %[ − 2] proPSA and phi with the aggressiveness of the tumor corroborate the clinical usefulness of these tests. However, more studies are necessary in order to confirm these data and, specially, in order to define the most appropriate cut-off for %[ − 2] proPSA and phi. 
